Toll Free: 1-888-928-9744

Smallpox - Pipeline Review, H2 2016

Published: Jul, 2016 | Pages: 84 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Smallpox - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Smallpox - Pipeline Review, H2 2016', provides an overview of the Smallpox pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Smallpox, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Smallpox and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Smallpox
- The report reviews pipeline therapeutics for Smallpox by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Smallpox therapeutics and enlists all their major and minor projects
- The report assesses Smallpox therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Smallpox

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Smallpox
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Smallpox pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Smallpox Overview 7 Therapeutics Development 8 Pipeline Products for Smallpox - Overview 8 Pipeline Products for Smallpox - Comparative Analysis 9 Smallpox - Therapeutics under Development by Companies 10 Smallpox - Therapeutics under Investigation by Universities/Institutes 11 Smallpox - Pipeline Products Glance 12 Late Stage Products 12 Early Stage Products 13 Smallpox - Products under Development by Companies 14 Smallpox - Products under Investigation by Universities/Institutes 15 Smallpox - Companies Involved in Therapeutics Development 16 Bavarian Nordic A/S 16 BioFactura, Inc. 17 CEL-SCI Corporation 18 Chimerix, Inc. 19 CJ HealthCare Corp. 20 EpiVax, Inc. 21 SIGA Technologies, Inc. 22 Takeda Pharmaceutical Company Limited 23 Tonix Pharmaceuticals Holding Corp. 24 Smallpox - Therapeutics Assessment 25 Assessment by Monotherapy Products 25 Assessment by Combination Products 26 Assessment by Target 27 Assessment by Mechanism of Action 29 Assessment by Route of Administration 31 Assessment by Molecule Type 33 Drug Profiles 35 (plague + small pox) vaccine - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 24a - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 brincidofovir - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 CEL-1000 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 CJ-40011 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 imatinib mesylate - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 Monoclonal Antibodies for Infectious Disease - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 Monoclonal Antibody for Smallpox - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 nilotinib - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 PL-801 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 SCV-305 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 small pox vaccine - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 smallpox vaccine - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 smallpox vaccine - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 tecovirimat - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 VIR-002 - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 Smallpox - Dormant Projects 71 Smallpox - Discontinued Products 73 Smallpox - Product Development Milestones 74 Featured News & Press Releases 74 Jun 15, 2016: Bavarian Nordic Announces Expansion of IMVAMUNE Orders from Canadian Government 74 Feb 24, 2016: FDA Concurs on Clinical Dose for SIGA's Tecovirimat Antiviral 74 Feb 08, 2016: Chimerix Presents Positive Results From Brincidofovir Pivotal Study in Animal Model for Smallpox 74 Dec 24, 2015: Delaware Supreme Court Affirms Chancery Court Ruling in Favor of PharmAthene 75 Sep 14, 2015: Chimerix and BARDA Announce Contract Extension of $13.0 Million for the Continued Development of Brincidofovir for Smallpox 75 Jul 23, 2015: Chimerix Announces Positive Topline Results From Brincidofovir Pivotal Study in Animal Model for Smallpox 76 Jul 07, 2015: Bavarian Nordic Receives Order for IMVAMUNE Smallpox Vaccine from the U.S. Government Valued at USD 133 Million 76 May 13, 2015: Bavarian Nordic Announces Positive Results from Two Pivotal Clinical Studies of IMVAMUNE Smallpox Vaccine 77 Jan 16, 2015: SIGA Technologies Appeals Judgment of Delaware Court of Chancery 78 Jan 07, 2015: Delaware Court of Chancery Issues Order Specifying Amount Of Lump Sum Expectation Damages Payable To PharmAthene; Total Award When Finalized, Including Pre-Judgment Interest, Attorneys' And Expert Witness Fees, Estimated To Be In Excess Of $190 Million 78 Dec 23, 2014: Chimerix Provides Recap of 2014 Events 79 Oct 04, 2014: Bavarian Nordic Announces Exercise of Contract Option by the U.S. Government for Continued Supply of IMVAMUNE Smallpox Vaccine 80 Sep 04, 2014: Bavarian Nordic Announces Exercise Of Contract Option By The U.S. Government For Continued Supply Of Imvamune Smallpox Vaccine 80 Sep 02, 2014: Chimerix and BARDA Announce Continued Partnership in the Development of Brincidofovir for Smallpox 81 Aug 26, 2014: Bavarian Nordic Receives Order from the Canadian Government to Supply IMVAMUNE Smallpox Vaccine 81 Appendix 83 Methodology 83 Coverage 83 Secondary Research 83 Primary Research 83 Expert Panel Validation 83 Contact Us 83 Disclaimer 84
List of Tables
Number of Products under Development for Smallpox, H2 2016 8 Number of Products under Development for Smallpox - Comparative Analysis, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Number of Products under Investigation by Universities/Institutes, H2 2016 11 Comparative Analysis by Late Stage Development, H2 2016 12 Comparative Analysis by Early Stage Development, H2 2016 13 Products under Development by Companies, H2 2016 14 Products under Investigation by Universities/Institutes, H2 2016 15 Smallpox - Pipeline by Bavarian Nordic A/S, H2 2016 16 Smallpox - Pipeline by BioFactura, Inc., H2 2016 17 Smallpox - Pipeline by CEL-SCI Corporation, H2 2016 18 Smallpox - Pipeline by Chimerix, Inc., H2 2016 19 Smallpox - Pipeline by CJ HealthCare Corp., H2 2016 20 Smallpox - Pipeline by EpiVax, Inc., H2 2016 21 Smallpox - Pipeline by SIGA Technologies, Inc., H2 2016 22 Smallpox - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 23 Smallpox - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2016 24 Assessment by Monotherapy Products, H2 2016 25 Assessment by Combination Products, H2 2016 26 Number of Products by Stage and Target, H2 2016 28 Number of Products by Stage and Mechanism of Action, H2 2016 30 Number of Products by Stage and Route of Administration, H2 2016 32 Number of Products by Stage and Molecule Type, H2 2016 34 Smallpox - Dormant Projects, H2 2016 71 Smallpox - Dormant Projects (Contd..1), H2 2016 72 Smallpox - Discontinued Products, H2 2016 73



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify